Nymox Pharmaceutical Corporation (NYMXF)

Nymox Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.07	0.07	1.4	0.83	3.61
Cash & Short-Term Investments	0.07	0.07	1.4	0.83	3.61
Cash Growth	5.71%	-95.01%	69.04%	-77.02%	-31.08%
Other Receivables	0.03	0.01	0.01	0.01	0.02
Receivables	0.03	0.01	0.01	0.01	0.02
Inventory	-	-	-	0.03	0.03
Prepaid Expenses	0.02	0.02	0.02	0.13	0.2
Other Current Assets	0.54	0.53	0.03	0.03	0.03
Total Current Assets	0.65	0.63	1.46	1.04	3.89
Property, Plant & Equipment	0	0	0.17	0.41	0.45
Total Assets	0.65	0.63	1.63	1.44	4.34
Accounts Payable	4.12	3.02	1.7	1.27	1.4
Accrued Expenses	0.03	0.03	0.24	0.29	0.32
Short-Term Debt	3.29	0.75	-	-	-
Current Portion of Leases	-	-	0.17	0.23	0.19
Other Current Liabilities	-	-	-	-	0.05
Total Current Liabilities	7.43	3.8	2.11	1.79	1.97
Long-Term Leases	-	-	-	0.16	0.23
Total Liabilities	7.43	3.8	2.11	1.95	2.2
Common Stock	173.88	173.82	171.67	165.06	151.72
Additional Paid-In Capital	28.01	27.78	26.99	27.58	31.04
Retained Earnings	-212.47	-207.98	-199.14	-192.56	-180.03
Comprehensive Income & Other	3.81	3.21	-	-0.59	-0.59
Total Common Equity	-6.78	-3.17	-0.48	-0.51	2.15
Shareholders' Equity	-6.78	-3.17	-0.48	-0.51	2.15
Total Liabilities & Equity	0.65	0.63	1.63	1.44	4.34
Total Debt	3.29	0.75	0.17	0.39	0.43
Net Cash (Debt)	-3.21	-0.68	1.23	0.44	3.19
Net Cash Growth	-	-	180.18%	-86.22%	-37.45%
Net Cash Per Share	-0.03	-0.01	0.01	0.01	0.04
Filing Date Shares Outstanding	94.54	93.54	91.27	90.28	78.71
Total Common Shares Outstanding	94.54	93.54	90.52	85.55	77.96
Working Capital	-6.78	-3.18	-0.65	-0.75	1.93
Book Value Per Share	-0.07	-0.03	-0.01	-0.01	0.03
Tangible Book Value	-6.78	-3.17	-0.48	-0.51	2.15
Tangible Book Value Per Share	-0.07	-0.03	-0.01	-0.01	0.03
Machinery	0.6	0.6	0.59	0.59	0.59

Updated Jan 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.